novo nordisk cuts glp-1 drug prices for cash-paying customers. Wegovy and Ozempic by 50% Eli Lilly and Novo Nordisk

Obesity is a network disease involving appetite regulation, reward signaling, gut-brain hormones, and energy expenditure pathways

26,27 Drug Efficacy and Side Effects in Clinical Trials The first GLP-1RA that received FDA approval was put on the market in 2005 under the name exenatide

Incretin analogs, a class of neurohormones that act in a multimodal way, represent some of the most advanced options in anti-obesity pharmacotherapy

For participants receiving 40 mg daily of oral semaglutide, three different dose-titration protocols were used where patients were titrated up to the full 40 mg dose in 6 weeks (fast dose escalation), 12 weeks (standard dose escalation), or 24 weeks (slow dose escalation)

Rare: Potential risk of NAION (as discussed)